ACTG A5321
Decay of HIV-1 Reservoirs in Subjects on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

Brief Description: AHRC (pronounced “ARC”) is a study of differences and changes over time in HIV reservoirs (groups of HIV infected cells that 'hide' from anti-HIV medications). Participants will attend visits twice a year for about 7 years. At these visits, blood and a small amount of hair will be collected from all participants. Some participants who meet additional criteria may be asked to have two additional procedures:

Rectal biopsy - a procedure that allows the collection of small pieces of rectal tissue
Leukapheresis - a procedure to collect white blood cells

These additional procedures are optional and will only start after a participant has been in the study at least 6 months. If you choose to participate in this study, you will not be required to undergo a biopsy or leukapheresis

Purpose of this Study:
This study is being done to try to answer questions about the ways that HIV infection is controlled. This may have to do with a person’s viral load and CD4 count, when they started their anti-HIV medications, and genetic factors.

To Enter Study:
You must be in one of the following three groups:
- Group 1: Participated in ACTG study A5276s or A5001. If you were a part of A5001 you must have also participated in one of these other studies: ACTG 384, A5095, A5142, A5202, or A5257.
- Group 2: Began your anti-HIV medications during the very early part of your HIV infection
- Group 3: Had a viral load less than 500 copies/mL prior to starting any anti-HIV medications.

Additionally, you must:
- Be a HIV-infected man or woman, ≥ 18 years of age
- Be taking anti-HIV medications that have been controlling your viral load for 1-2 years (depending on which Group you will be in).
- Have never stopped your anti-HIV medications for greater than 3 weeks.
- Have no active Hepatitis B or C infection, an autoimmune disorder or a condition requiring steroid therapy.

Treatment:
You must be taking and planning to continue your current anti-HIV medications. These medications will not be supplied through this study.

Duration of Study: You will be expected to stay in the study for about 7 years

For more information contact: Your study nurse at Vanderbilt Therapeutic Clinical Research Site. The main phone number is 615-936-2642.

Date of Approval: 8/30/2013